Dr. Patricia Tang is a medical oncologist at the Tom Baker Cancer Centre and a Clinical Associate Professor at the Cumming School of Medicine, University of Calgary. She specializes in the treatment of breast and gastrointestinal malignancies. Dr. Tang completed an Investigational New Drug fellowship at Princess Margaret Cancer Centre, University of Toronto. She is the Provincial Gastrointestinal Cancer Tumor Group Leader for Alberta. She is the Centre Representative to the Canadian Cancer Clinical Trials Group for Calgary, a member of the OICR Clinical Trials Subcommittee, and was awarded the Ralph Meyer Phase III Program Young Investigator Award in 2016. She has reviewed grants for: Breast Cancer Now (United Kingdom), Saskatchewan Cancer Agency, Canadian Breast Cancer Foundation, and Pancreatic Cancer Canada. She was awarded the Ralph Meyer Phase III Program Young Investigator Award in 2016. She is currently a member of the Royal College of Physicians and Surgeons of Canada Nucleus Committee for Medical Oncology. She received the 2016 Luminary Award for Teaching in the Department of Oncology. Her research interests are primarily in clinical trials as well as health services.
Area of Focus
Summary of Research
Key Publications:
- Jonker D, Tang PA, Kennecke H, Welch S, Cripps C, Asmis T, Chalcha H, Tomiak A, Lim h, Ko Y, Chen E, Alcindor T, Goffin J, Korpanty G, Feilotter H, Tsao M, Thies A, Tu D, Seymour L. A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210 Canadian Cancer Trials Group Trial. Clinical Colorectal Cancer. 2018 (17): 231-239
- Ezeife D, Parimi S, Cusano E, Smith M, Truong T, Raissouni S, Lin Y, Monzon J, Li H, Tam V, Tang PA. The evolution of metastatic colorectal cancer clinical trials: application of the ASCO framework value. Journal of the National Comprehensive Cancer Network. Aug 2017; 15(8):1005-1013
- Andrew P, Vickers MM, O’Connor S, Valdes M, Tang PA. Media reporting of practice-changing clinical trials in oncology – a North American perspective. The Oncologist 2016 Mar;21(3):269-78 2016
- Ezeife DA, Truong TH, Heng DY, Bourque S, Welch SA, Tang PA. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration. Cancer 2015, 121(10):1688-93
- Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol; 2007, 25(29):4562-8.
Area Of Focus
Summary Of Research
Key Publications:
- Jonker D, Tang PA, Kennecke H, Welch S, Cripps C, Asmis T, Chalcha H, Tomiak A, Lim h, Ko Y, Chen E, Alcindor T, Goffin J, Korpanty G, Feilotter H, Tsao M, Thies A, Tu D, Seymour L. A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210 Canadian Cancer Trials Group Trial. Clinical Colorectal Cancer. 2018 (17): 231-239
- Ezeife D, Parimi S, Cusano E, Smith M, Truong T, Raissouni S, Lin Y, Monzon J, Li H, Tam V, Tang PA. The evolution of metastatic colorectal cancer clinical trials: application of the ASCO framework value. Journal of the National Comprehensive Cancer Network. Aug 2017; 15(8):1005-1013
- Andrew P, Vickers MM, O’Connor S, Valdes M, Tang PA. Media reporting of practice-changing clinical trials in oncology – a North American perspective. The Oncologist 2016 Mar;21(3):269-78 2016
- Ezeife DA, Truong TH, Heng DY, Bourque S, Welch SA, Tang PA. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration. Cancer 2015, 121(10):1688-93
- Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol; 2007, 25(29):4562-8.